Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age21+
SponsorKyle Greenway

About this trial

The goal of this pilot clinical trial is to learn whether it is feasible to individually tailor psilocybin-assisted psychotherapy (PAP) for people with treatment-resistant depression (TRD) based on their personal preferences. The study also aims to explore whether two different psychotherapy styles, music-centered and mindfulness-centered, influence how people respond to psilocybin treatment.

The main questions it aims to answer are:

* Is it feasible to conduct a patient-preference randomized trial of psilocybin-assisted psychotherapy? * Does receiving a preferred psychotherapy style improve treatment experiences or outcomes? * How do music-centered and mindfulness-centered PAP approaches compare in their effects on improving mood and well-being?

Researchers will compare music-centered PAP to mindfulness-centered PAP to see if aligning psychotherapy with individual preferences is a practical and potentially beneficial approach for improving treatment efficacy and tolerability.

Participants will:

* Be adults with treatment-resistant depression * Receive two 25 mg psilocybin (PEX010, Filament Health) sessions, spaced four weeks apart * Experience one session with music-centered psychotherapy and one with mindfulness-centered psychotherapy * Before treatment, rate their preference for the two psychotherapy approaches * Be randomly assigned to receive their preferred or non-preferred approach first, followed by the other * Complete preparation and integration sessions before and after each psilocybin session

This feasibility trial will also collect information on participants' cultural and personal factors influencing psychotherapy preferences using a modified Cultural Formulation Interview, and explore physiological measures of therapeutic alliance, an important factor in psychotherapy outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

At least 21 years of age at screening.

Diagnosis of unipolar Major Depressive Disorder (MDD) according to diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), confirmed by a study psychiatrist using the Mini International Neuropsychiatric Interview (MINI) version 7.0.2.

Failure to achieve remission from at least two trials of evidence-based oral antidepressants, in the current episode, of adequate dose and duration.

Moderate to severe symptoms according to the clinician-administered Montgomery-Åsberg Depression Rating Scale (MADRS): total score ≥ 25 on screening.

Disqualifiers

Deemed to be greater than low risk of suicide on psychiatric interview.

Currently or previously diagnosed with any of the following, according to available information and psychiatric interview: major depression with psychotic features, schizophrenia spectrum or other psychotic disorders, and/or bipolar affective disorder I or related disorders.

Current or past diagnosis of personality disorder deemed to pose a significant risk for safety and/or trial compliance.

Family history (first-degree relative) of psychosis.

Trial design

Design model

Crossover

Treatments tested in this trial

  • Psilocybin 25mg

    Drug

    Psilocybin 25mg

  • Music-centered psilocybin-assisted therapy

    Other intervention

    Psilocybin therapy emphasizing the use of music.

  • Mindfulness-centered psilocybin-assisted therapy

    Other intervention

    Psilocybin therapy emphasizing the use of guided mindfulness.

Treatment groups

16 Participants
are divided into 2 treatment groups
Group A: Preferred treatmentExperimental treatment 3 interventions
Group B: Non-preferred treatmentExperimental treatment 3 interventions

Trial outcomes

Primary outcomes

1

Enrollment Feasibility

The proportion of participants screened as eligible who enroll in the trial.

Time frame
From screening through enrollment
2

Overall Trial Completion Feasibility

The proportion of enrolled participants who complete the trial, defined as attending ≥ 90% of required study visits.

Time frame
From enrollment through the end of active treatment (Week 10)
3

Trial Completion by Preference Assignment

The proportion of participants in the preferred and non-preferred treatment groups who complete ≥ 90% of study visits.

Time frame
From enrollment through the end of active treatment (Week 10)
4

Distribution of Treatment Preferences

The proportion of participants who choose the music-centered versus the mindfulness-centered approach as their preferred treatment at baseline.

Time frame
Baseline

Secondary outcomes

1

Rate of Adverse Events in Music- versus Mindfulness-centered Interventions

Rates of adverse events in participants receiving music-centered versus mindfulness-centered approaches. Adverse events include any treatment-emergent symptoms reported by participants or observed by study staff.

Time frame
Baseline, Week 5 (primary endpoint), Week 11 (follow-up)
2

Rate of Adverse Events in Preferred vs. Non-Preferred Interventions

Rates of adverse events in participants receiving their preferred versus non-preferred interventions. Adverse events include any treatment-emergent symptoms reported by participants or observed by study staff.

Time frame
Baseline, Week 5 (primary endpoint), Week 11 (follow-up)
3

Rate of Participant Drop-Outs in Preferred vs. Non-Preferred Interventions

Rates of participant drop-outs in participants receiving their preferred versus non-preferred interventions. Drop-out is defined as missing more than 10% of scheduled visits during the active treatment period.

Time frame
Baseline, Week 5 (primary endpoint), Week 11 (follow-up)
4

Rate of Participant Drop-Outs in Music- versus Mindfulness-centered Interventions

Rates of participant drop-outs in participants receiving music-centered versus mindfulness-centered approaches. Drop-out is defined as missing more than 10% of scheduled visits during the active treatment period.

Time frame
Baseline, Week 5 (primary endpoint), Week 11 (follow-up)

Other outcomes

1

Therapeutic Alliance - Patient (WAI-SR)

The Working Alliance Inventory - Short Revised (WAI-SR, Patient version) is a 12-item, self-reported measure assessing patients' perception of the therapeutic alliance during treatment sessions. Items assess agreement, collaboration, and bond with the therapist, including understanding goals, agreement on tasks, mutual respect, and perceived care and support. Participants rate each item on a 5-point Likert scale ranging from 1 (seldom) to 5 (always). Total scores are calculated by summing item responses, with possible scores ranging from 12 to 60. Higher scores indicate a stronger therapeutic alliance. Scores will be compared by preference group (preferred vs. non-preferred) and therapeutic approaches (music-centered versus mindfulness-centered).

Time frame
Weeks 1 and 7 (preparation sessions), Weeks 3 and 9 (treatment and integration sessions)
2

Therapeutic Alliance - Therapist (WAI-SRT)

The Working Alliance Inventory - Short Revised (WAI-SR, Therapist version) is a 10-item, self-reported measure assessing therapists' perception of the therapeutic alliance during treatment sessions. Items evaluate agreement on goals and tasks, mutual understanding, collaboration, respect, and concern for the patient's welfare. Therapists rate each item on a 5-point Likert scale ranging from 1 (seldom) to 5 (always). Total scores are calculated by summing item responses, with possible scores ranging from 10 to 50. Higher scores indicate a stronger perceived therapeutic alliance. Scores will be compared by preference group (preferred vs. non-preferred) and therapeutic approaches (music-centered versus mindfulness-centered).

Time frame
Weeks 1 and 7 (preparation sessions), Weeks 3 and 9 (treatment and integration sessions)
3

Linguistic Synchrony

Linguistic synchrony between the participant and clinicians will be quantified using Natural Language Processing (NLP) applied to session transcripts. The measure has no predefined minimum or maximum value; higher values indicate greater alignment in language use between the participant and clinicians. Scores will be compared by preference group (preferred vs. non-preferred) and therapeutic approaches (music-centered versus mindfulness-centered).

Time frame
Weeks 1 and 7 (preparation sessions), Weeks 3 and 9 (treatment and integration sessions)
4

Cardiovascular Synchrony

Cardiovascular synchrony between the participant and clinicians will be assessed using electrocardiography (ECG)-derived heart rate variability (HRV) and respiratory sinus arrhythmia (RSA). A validated surrogate synchrony method will be applied to quantify the extent of physiological alignment between the participant and clinicians during therapy sessions. The measure has no predefined minimum or maximum value; higher values indicate greater cardiovascular synchrony. Scores will be compared by preference group (preferred vs. non-preferred) and therapeutic approaches (music-centered versus mindfulness-centered).

Time frame
Weeks 1 and 7 (preparation sessions), Weeks 3 and 9 (treatment and integration sessions)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Kyle Greenway

Lead sponsor

Sir Mortimer B. Davis - Jewish General Hospital

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: